Botulinum Toxin Treatment for Limb Spasticity in Childhood Cerebral Palsy

Area of Science:

• Pediatrics
• Neurology
• Rehabilitation Medicine

Background:

• Cerebral palsy (CP) is a leading cause of chronic childhood disability, affecting 2-2.5 per 1000 births.
• CP often results in cognitive delays and ambulatory dysfunction.
• Botulinum toxin (BTX) is increasingly utilized for managing spastic and dystonic muscles in CP.

Purpose of the Study:

• To highlight the utility of botulinum toxin (BTX) in treating children with cerebral palsy (CP).
• To provide comprehensive information on BTX administration techniques, potential side effects, and resistance.
• To detail the specific application of BTX in upper and lower limb muscles affected by CP.

Main Methods:

• Review of current literature and clinical practices regarding BTX use in pediatric CP.
• Discussion of combined therapeutic approaches including physiotherapy, casting, and orthotics alongside BTX injections.
• Analysis of BTX's role in preventing or delaying surgical interventions.

Main Results:

• BTX effectively manages spasticity and dystonia in pediatric CP, alleviating pain and preventing deformities.
• Combination therapy (BTX, physiotherapy, casting, orthotics) can delay or reduce the necessity for surgical procedures.
• BTX offers targeted treatment for upper and lower limb muscles, improving function in children with CP.

Conclusions:

• Botulinum toxin (BTX) is a valuable therapeutic tool in the multidisciplinary management of cerebral palsy (CP) in children.
• BTX, particularly when combined with other conservative treatments, plays a crucial role in optimizing functional outcomes and minimizing surgical needs.
• Understanding BTX administration, potential adverse effects, and resistance is key to its successful application in pediatric CP treatment.